

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6339464

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
IPSEN INNOVATION S.A.S.	10/09/2018
RECEIVING PARTY DATA	
Name:	IPSEN BIOPHARM LTD.
Street Address:	ASH ROAD, WREXHAM INDUSTRIAL ESTATE
City:	WREXHAM
State/Country:	GREAT BRITAIN
Postal Code:	LL13 9UF
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16346436
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174304740821
Email:	docketing@mcneillbaur.com
Correspondent Name:	MCNEILL BAUR PLLC
Address Line 1:	125 CAMBRIDGE PARK DRIVE
Address Line 2:	SUITE 301
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02140
ATTORNEY DOCKET NUMBER:	01208-0016-00US
NAME OF SUBMITTER:	RICHARD C. KING
SIGNATURE:	/Richard C. King/
DATE SIGNED:	10/07/2020
Total Attachments: 3	
source=2020-06-23_01208-0016-00US_Assignment_Exctd_Ipsen_Innovation_SAS-Ipsen_BiopharmLTD#page1.tif	
source=2020-06-23_01208-0016-00US_Assignment_Exctd_Ipsen_Innovation_SAS-Ipsen_BiopharmLTD#page2.tif	
source=2020-06-23_01208-0016-00US_Assignment_Exctd_Ipsen_Innovation_SAS-Ipsen_BiopharmLTD#page3.tif	

ASSIGNMENT

For valuable consideration, the sufficiency of which is hereby acknowledged, **IPSEN INNOVATION S.A.S.**, a company existing under the laws of France and having a principal place of business at Z.I. de Courtaboeuf – 5 avenue du Canada, Les Ulis, FR 91940, (hereinafter Assignor) confirms that it has assigned and/or hereby assigns to **IPSEN BIOPHARM LTD.**, a company existing under the laws of England and Wales and having a place of business at Ash Road, Wrexham Industrial Estate, Wrexham, UK LL13 9UF, its successors and assigns (hereinafter Assignee), the entire right, title and interest throughout the world in the inventions and discoveries disclosed in:

PCT International Patent Application entitled METHODS FOR TREATING GASTRIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN AND OXALIPLATIN filed November 1, 2017 and assigned Application Number PCT/GB2017/053293, and its title subsequently amended by the PCT International Searching Authority to TREATING GASTRIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN, OXALIPLATIN, 5-FLUORURACIL (AND LEUCOVORIN); referred to as the “Application” this assignment including: (1) said Application and any other application, and/or provisional application, which has been or shall be filed for said inventions in any country of the world, including any and all divisional, continuing, or substitute applications based thereon; (2) any and all patents, utility models and design registrations granted for any of said inventions in any country of the world, and all registrations, confirmations, renewals, reexaminations, reissues, Patent Term Extensions and extensions thereof; (3) the right to claim priority based on the filing date of said PCT International Patent Application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; (4) the right to apply in all countries in Assignors’ names or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventor(s) certificate(s) for said inventions; and (5) the right to bring, make, oppose, defend and/or appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action

whether arising from ownership or otherwise, in respect of any such patent applications, patents or inventions, whether occurring before on or after the date of this Assignment.


Assignor hereby authorizes and requests the issuing authority to issue any and all patents claiming said inventions to Assignee or its successors and assigns. Assignor further agrees that, upon request and without further compensation, but at no out-of-pocket expense to Assignor and Assignor's successors and/or assigns, will perform such lawful acts and will sign such further applications, assignments, Preliminary Statements and other lawful documents as Assignee may reasonably request to effectuate fully this assignment, including by way of example, but not of limitation, the following acts:

- A. Prompt execution of all lawful oaths, affidavits and/or supplemental oaths required or deemed advisable by Assignee to further the prosecution of any application or applications for letters patent relating to the subject matter of this Assignment;
- B. To cooperate to the best of our ability in the execution of all lawful documents, the production of evidence, and the giving of testimony in interference, opposition, nullification or infringement proceedings involving the subject matter of this Assignment.

This Assignment will have effect from the filing date of the above-identified Application.

This Assignment shall be governed by the laws of France.

IPSEN INNOVATION S.A.S.



Name: Janice M. Klunder

Title: VP, Head of Global Intellectual Property

Dawn M. MacPherson
WITNESS

Oct 9, 2018
Date

[WITNESS NAME] Dawn MacPherson

Eileen J. Ennis
WITNESS

Oct 9, 2018
Date

[WITNESS NAME] Eileen J Ennis

The undersigned officer of IPSEN BIOPHARM LTD. hereby acknowledges the foregoing executed confirmation of the transfer of rights on behalf of IPSEN BIOPHARM LTD.

IPSEN BIOPHARM LTD.

Janice M. Klunder

9-Oct-2018

Name: Janice M. Klunder

Date

Title: VP, Head of Global
Intellectual Property